GSK (LON:GSK) Given "Under review" Rating at JPMorgan Chase & Co.

Key Points

• GSK's stock has been given an "under review" rating by JPMorgan Chase & Co., which indicates a wait-and-see approach on the company's performance.
• The stock has a consensus rating of "Hold" from analysts, with price targets ranging from GBX 1,450 to GBX 2,100.
• Insider Wendy Becker purchased shares at an average cost of GBX 1,503, highlighting potential insider confidence in the company's prospects.

GSK (LON:GSK - Get Free Report)'s stock had its "under review" rating reissued by analysts at JPMorgan Chase & Co. in a report released on Friday,Digital Look reports.

GSK has been the subject of several other research reports. Berenberg Bank reissued a "hold" rating and issued a GBX 1,600 price target on shares of GSK in a report on Friday, July 18th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a GBX 1,450 price objective on shares of GSK in a research note on Thursday, July 31st. Finally, Shore Capital restated a "buy" rating and issued a GBX 2,100 target price on shares of GSK in a research report on Wednesday, August 27th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of GBX 1,637.50.

GSK Stock Down 0.5%

GSK stock opened at GBX 1,638 on Friday. GSK has a one year low of GBX 1,242.50 and a one year high of GBX 1,684.50. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The firm's fifty day moving average is GBX 1,462.72 and its 200 day moving average is GBX 1,434.38. The firm has a market cap of £65.97 billion, a PE ratio of 1,980.65, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported GBX 75.30 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, research analysts forecast that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling at GSK

In related news, insider Wendy Becker purchased 526 shares of the company's stock in a transaction dated Friday, September 19th. The stock was acquired at an average cost of GBX 1,503 per share, for a total transaction of £7,905.78. In the last 90 days, insiders purchased 561 shares of company stock worth $841,184. Insiders own 0.20% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.